Clinical Trials Logo

Clinical Trial Summary

A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01544114
Study type Interventional
Source Horizon Pharma Ireland, Ltd., Dublin Ireland
Contact
Status Completed
Phase Phase 4
Start date April 2012
Completion date February 2015

See also
  Status Clinical Trial Phase
Recruiting NCT05534347 - Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
Recruiting NCT05710640 - Transcutaneous Vagus Nerve Stimulation (tcVNS) in JIA Phase 2
Active, not recruiting NCT03725007 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis Phase 1
Recruiting NCT03245801 - CAPRI National Juvenile Idiopathic Arthritis Registry
Completed NCT05000216 - COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Phase 2